The BrainDrugs-D study uses multimodal neuroimaging combined with self-report measures, clinical and molecular markers to identify clinically relevant predictors that can identify subtypes of major depressive disorder (MDD) and, in a naturalistic setting, predict treatment response to standard antidepressive treatment. The cohorts are followed in nationwide health registries.
Age between 18 and 65 years
Fulfilment of International Classification of Diseases version 10 diagnostic criteria for a primary depressive episode (i.e., not secondary to known organic or other psychiatric disorder).
Referral to a treatment package for single-episode depression.
Psychosis or psychotic symptoms
History of severe head trauma
Somatic disease associated with morphological brain changes (e.g., brain tumour)
Insufficient Danish language skills to complete questionnaires and cognitive testing
Rigshospitalet, Denmark
Lead sponsor
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Collaborator
Center for Integrated Molecular Brain Imaging, Copenhagen, Denmak
Collaborator
Lundbeck Foundation
Collaborator